Demonstration of an intrinsic relationship between endogenous c-peptide concentration and determinants of glycemic control in type 1 diabetes following islet transplantation

Diabetes Care

Volumn 38, Issue 1, 2015, Pages 105-112

  Brooks, Augustin M ^a   Oram, Richard ^b   Home, Philip ^a   Steen, Nick ^c   Shaw, James A M ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b Peninsula NIHR Clinical Research Facility   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; HEMOGLOBIN A1C; INSULIN; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; CELL FUNCTION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MIDDLE AGED; MIXED MEAL TOLERANCE TEST; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; BLOOD; DIABETES MELLITUS, TYPE 1; METABOLISM; PROSPECTIVE STUDY;

ADULT; BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 1; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; INSULIN; ISLETS OF LANGERHANS TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84920052627     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-1656     Document Type: Article

References (34)

1. Oram RA, Jones AG, Besser RE, et al. The majority of patients with long-duration type 1 diabetes are insulinmicrosecretors and have functioning beta cells. Diabetologia 2014;57:187-191
2. Wang L, Lovejoy NF, Faustman DL. Persistence of prolonged C-peptide production in type 1 diabetes as measured with an ultrasensitive Cpeptide assay. Diabetes Care 2012;35:465-470
3. Keenan HA, Sun JK, Levine J, et al. Residual insulin production and pancreatic β-cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes 2010;59:2846-2853
4. Greenbaum CJ, Mandrup-Poulsen T, McGee PF, et al.; Type 1 Diabetes Trial Net Research Group; European C-Peptide Trial Study Group. Mixed-meal tolerance test versus glucagon stimulation test for the assessment of betacell function in therapeutic trials in type 1 diabetes. Diabetes Care 2008;31:1966-1971
5. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005;352:2598-2608
6. Brooks AM, Walker N, Aldibbiat A, et al Attainment of metabolic goals in the integrated UK islet transplant programwith locally isolated and transported preparations. Am J Transplant 2013;13:3236-3243
7. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the Diabetes Control and Complications Trial. A randomized, controlled trial. Ann Intern Med 1998;128:517-523
8. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes- related complications in the Diabetes Control and Complications Trial. Diabetes Care 2003;26:832-836
9. Lachin JM, McGee P, Palmer JP; DCCT/EDIC Research Group. Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes 2014;63:739-748
10. Vantyghem MC, Raverdy V, Balavoine AS, et al. Continuous glucose monitoring after islet transplantation in type 1 diabetes: An excellent graft function (b-score greater than 7) Is required to abrogate hyperglycemia, whereas a minimal function is necessary to suppress severe hypoglycemia (b-score greater than 3). J Clin Endocrinol Metab 2012;97:E2078-E2083
11. Kessler L, Passemard R, Oberholzer J, et al.; GRAGIL Group. Reduction of blood glucose variability in type 1 diabetic patients treated by pancreatic islet transplantation: Interest of continuous glucose monitoring. Diabetes Care 2002;25:2256-2262
12. Faradji RN, Monroy K, Riefkohl A, et al. Continuous glucose monitoring system for early detection of graft dysfunction in allogenic islet transplant recipients. Transplant Proc 2006;38: 3274-3276
13. Gorn L, Faradji RN, Messinger S, et al. Impact of islet transplantation on glycemic control as evidenced by a continuous glucose monitoring system. J Diabetes Sci Tech 2008; 2:221-228
14. Geiger MC, Ferreira JV, Hafiz MM, et al. Evaluation of metabolic control using a continuous subcutaneous glucose monitoring system in patients with type 1 diabetes mellitus who achieved insulin independence after islet cell transplantation. Cell Transplant 2005;14:77-84
15. Paty BW, Senior PA, Lakey JR, Shapiro AM, Ryan EA. Assessment of glycemic control after islet transplantation using the continuous glucose monitor in insulin-independent versus insulin-requiring type 1 diabetes subjects. Diabetes Technol Ther 2006;8:165-173
16. Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: A report from the, American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005;28:1245-1249
17. Aldibbiat AHG, Zhao M, Holliman GN, et al. Validation of islet transport from a geographically distant isolation center enabling equitable access and National Health Service funding of a clinical islet transplant program for England. Cell Med 2012;21:97-104
18. Huang GC, Zhao M, Jones P, et al. The development of new density gradient media for purifying human islets and islet-quality assessments. Transplantation 2004;77:143-145
19. Barton FB, Rickels MR, Alejandro R, et al. Improvement in outcomes of clinical islet transplantation: 1999-2010. Diabetes Care 2012;35: 1436-1445
20. Kovatchev BP, Otto E, Cox D, Gonder- Frederick L, Clarke W. Evaluation of a new measure of blood glucose variability in diabetes. Diabetes Care 2006;29:2433-2438
21. Kovatchev BP, Cox DJ, Kumar A, Gonder- Frederick L, Clarke WL. Algorithmic evaluation of metabolic control and risk of severe hypoglycemia in type 1 and type 2 diabetes using self-monitoring blood glucose data. Diabetes Technol Ther 2003;5:817-828
22. Hill NR, Oliver NS, Choudhary P, Levy JC, Hindmarsh P, Matthews DR. Normal reference range for mean tissue glucose and glycemic variability derived from continuous glucose monitoring for subjects without diabetes in different ethnic groups. Diabetes Technol Ther 2011;13: 921-928
23. Kovatchev BP, Cox DJ, Gonder-Frederick LA, Young-Hyman D, Schlundt D, Clarke W. Assessment of risk for severe hypoglycemia among adults with IDDM: validation of the low blood glucose index. Diabetes Care 1998;21: 1870-1875
24. Kovatchev BP, Cox DJ, Gonder-Frederick L, Clarke WL. Methods for quantifying selfmonitoring blood glucose profiles exemplified by an examination of blood glucose patterns in patients with type 1 and type 2 diabetes. Diabetes Technol Ther 2002;4:295-303
25. McCall AL, Cox DJ, Brodows R, Crean J, Johns D, Kovatchev B. Reduced daily risk of glycemic variability: Comparison of exenatide with insulin glargine. Diabetes Technol Ther 2009;11: 339-344
26. The DCCT Research Group. Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). J Clin Endocrinol Metab 1987;65: 30-36
27. Ryan EA, PatyBW, Senior PA, et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005;54:2060-2069
28. Rickels MR, Schutta MH, Mueller R, et al. Glycemic thresholds for activation of counterregulatory hormone and symptom responses in islet transplant recipients. J Clin Endocrinol Metab 2007;92:873-879
29. Vantyghem MC, Kerr-Conte J, Arnalsteen L, et al. Primary graft function, metabolic control, and graft survival after islet transplantation. Diabetes Care 2009;32:1473-1478
30. Ryan EA, Paty BW, Senior PA, Lakey JR, Bigam D, Shapiro AM. Beta-score: An assessment of beta-cell function after islet transplantation. Diabetes Care 2005;28:343-347
31. Gillard P, Hilbrands R, Van de Velde U, et al. Minimal functional β-cell mass in intraportal implants that reduces glycemic variability in type 1 diabetic recipients. Diabetes Care 2013;36: 3483-3488
32. Keenan DB, Mastrototaro JJ, Zisser H, et al. Accuracy of the Enlite 6-day glucose sensor with guardian and Veo calibration algorithms. Diabetes Technol Ther 2012;14:225-231
33. Clarke WL, Kovatchev B. Continuous glucose sensors: Continuing questions about clinical accuracy. J Diabetes Sci Tech 2007;1:669-675
34. Zung A, Zadik Z. Continuous subcutaneous glucose monitoring in children with type 1 diabetes. Pediatrics 2002;109:347